Gene Therapy

Leading the future of genetic medicine

Cutting-Edge Genetic Medicine

SXR Laboratories is at the forefront of gene therapy research, conducting trials for innovative genetic treatments including AAV vectors, CRISPR-based therapies, and gene editing technologies.

Our Expertise

AAV gene therapy trials
Lentiviral vector studies
CRISPR/Cas9 clinical trials
In vivo gene editing
Genetic disease treatments
Long-term safety monitoring

Foundational Technologies & Platforms

Gene Editing Tools

CRISPR-Cas9: Revolutionary gene-editing system that precisely cuts DNA at specific locations to delete, repair, or insert genes. The workhorse of modern gene editing, enabling correction of disease-causing mutations at their source.

Base Editors: Advanced CRISPR variants that can change single DNA letters without cutting both strands, offering precision with reduced off-target effects.

Prime Editing: Next-generation editing enabling precise insertions, deletions, and replacements without requiring DNA double-strand breaks.

Viral Vector Platforms

AAV (Adeno-Associated Virus): The primary engineered viral vector for in vivo gene therapy, delivering corrective genes directly into human cells. Multiple serotypes enable tissue-specific targeting (liver, muscle, eye, CNS).

Lentivirus: Viral vector commonly used for ex vivo gene therapy, particularly effective for modifying blood stem cells and immune cells outside the body before reinfusion.

Adenovirus: Non-integrating vector useful for transient gene expression and vaccine applications.

Gene Regulation Technologies

RNAi (RNA Interference): Using small interfering RNAs to silence disease-causing genes post-transcriptionally. ASOs (Antisense Oligonucleotides): Short synthetic DNA/RNA molecules that bind to target mRNA to modulate gene expression, successfully used in Spinal Muscular Atrophy. shRNA (Short Hairpin RNA): RNA molecules that trigger gene silencing, often delivered via viral vectors for sustained effect. mRNA Therapy: Delivering messenger RNA instructions to cells for temporary production of therapeutic proteins without permanently altering the genome.

Advanced Technology

We maintain specialized capabilities for gene therapy trials including viral vector characterization, biodistribution studies, and comprehensive immunogenicity assessments.

Integrated Research Excellence

Gene therapy demands cutting-edge integration across all research disciplines. Clinical Trials Management implements complex protocols for vector administration with specialized manufacturing chain-of-custody procedures. Regulatory Affairs navigates evolving gene therapy regulatory frameworks including IND submissions and RMAT designations. Quality Assurance maintains rigorous oversight of vector characterization, biodistribution studies, and long-term safety monitoring. Data Management tracks complex genetic endpoints and immunogenicity markers. Biostatistics designs trials appropriate for first-in-human gene therapies, while Medical Writing articulates novel mechanisms of action in comprehensive regulatory dossiers.